Theragen ETEX said Tuesday that it has registered a patent regarding the use of big data technology in immunotherapy research.
The company said this is the first time that a domestic biotech company obtained a patent in the field of providing biometrics data for cancer treatment.
The patented technology allows companies to store and manage various data obtained from living cells such as DNA and RNA safely and anonymously. It can also save cost and time of cryopreserving bio-tissues in liquid nitrogen or extracting derivatives from a new tissue each time.
The company expects the patented technology will improve the efficiency of research when used to analyze cancer pathogenesis.
“Theragen plans to start a big data business using genetic information,” Theragen ETEX CEO Hwang Tae-soon said. “We will use this patent as a core technology in future related business.”
<© Korea Biomedical Review, All rights reserved.>